Edwards Lifesciences gains 16.6% as guidance and trial data lift sentiment
Alpha Vantage · Simply Wall St · · AI-summarised by FinFlash
Edwards Lifesciences shares are up 16.6% over the past month and 18.2% year-to-date after positive third-quarter results, a raised full-year sales guidance and fresh clinical trial data. The stock trades near its average analyst target of Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.Understand the context